Subgroup analyses revealed similar survival for ACC-TNBC and IDC-TNBC; however, excellent survival was observed in HR+/Her2- breast-ACC patients compared to HR+/Her2- patients with breast-IDC. This evidence concerns the gene ERBB2 and medical procedure.